Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships
December 22, 2016 10:00 ET
|
Cellceutix Corporation
BEVERLY, Mass., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening
December 19, 2016 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment; Company Seeks to Develop World’s First p53-Modulating Oral Cancer Drug
December 15, 2016 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
December 07, 2016 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Results
November 14, 2016 16:30 ET
|
Cellceutix Corporation
Enrollment Underway in Phase 2b Study of Prurisol for Moderate to Severe Plaque Psoriasis Positive Initial Data Reported in Phase 2a Proof of Concept Open-Label Study of Brilacidin...
Cellceutix Announces Business Update Call at 10AM Eastern on November 15
November 09, 2016 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies including...
Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque Psoriasis
October 31, 2016 15:07 ET
|
Cellceutix Corporation
BEVERLY, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
October 26, 2016 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel Anti-Inflammatory Drug Candidate for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
October 10, 2016 07:00 ET
|
Cellceutix Corporation
BEVERLY, Mass., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTC: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...